Sign up to save your podcasts
Or
Share Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.
View all episodes
By BiotechTV
5
44 ratings
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.
More shows like BiotechTV - News
View all
Planet Money
30,636 Listeners
Odd Lots
1,872 Listeners
a16z Podcast
1,086 Listeners
The Readout Loud
325 Listeners
The Journal.
6,086 Listeners
Biotech 2050 Podcast
60 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,852 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
ACQ2 by Acquired
260 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
503 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners